Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
McKinsey
Colorcon
Mallinckrodt
Merck

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,629,345

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,629,345 protect, and when does it expire?

Patent 7,629,345 protects VYZULTA and is included in one NDA.

This patent has forty-nine patent family members in thirty-six countries.

Summary for Patent: 7,629,345
Title:Prostaglandin derivatives
Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Inventor(s): Ongini; Ennio (Milan, IT), Chiroli; Valerio (Milan, IT), Benedini; Francesca (Milan, IT), Del Soldato; Piero (Monza, IT)
Assignee: Nicox S.A. (Sophia Antipolis, FR)
Application Number:12/210,975
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,629,345

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes   Start Trial   Start Trial Y REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,629,345

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04100001Jan 5, 2004

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Medtronic
Express Scripts
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.